Cornerstone Therapeutics, Inc. (CRTX) Posts Q2 Loss of 17c/Share

August 9, 2012 7:31 AM EDT
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q2 EPS of ($0.17), $0.15 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $21.47 million versus the consensus estimate of $18.84 million.

For earnings history and earnings-related data on Cornerstone Therapeutics, Inc. (CRTX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings